Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level RB Moss, MMC Pryor, R Baillie, K Kudrycki, C Friedrich, M Reed, ... PLoS One 15 (6), e0234683, 2020 | 42 | 2020 |
Orchestration of ErbB3 signaling through heterointeractions and homointeractions M McCabe Pryor, MP Steinkamp, AM Halasz, Y Chen, S Yang, MS Smith, ... Molecular biology of the cell 26 (22), 4109-4123, 2015 | 32 | 2015 |
Mathematical simulation of membrane protein clustering for efficient signal transduction K Radhakrishnan, Á Halász, MM McCabe, JS Edwards, BS Wilson Annals of biomedical engineering 40, 2307-2318, 2012 | 26 | 2012 |
Dynamic transition states of ErbB1 phosphorylation predicted by spatial stochastic modeling MMC Pryor, ST Low-Nam, ÁM Halász, DS Lidke, BS Wilson, JS Edwards Biophysical journal 105 (6), 1533-1543, 2013 | 25 | 2013 |
Analytical Solution of Steady State Equations for Chemical Reaction Networks with Bilinear Rate Laws. AM Halász, HJ Lai, M McCabe Pryor, K Radhakrishnan, JS Edwards IEEE/ACM transactions on computational biology and bioinformatics/IEEE, ACM, 2013 | 17 | 2013 |
Quantitative Systems Pharmacology Model of the Amyloid Pathway in Alzheimer’s Disease: Insights into the Therapeutic Mechanisms of Clinical Candidates V Ramakrishnan, C Friedrich, C Witt, R Sheehan, M Pryor, JK Atwal, ... CPT: Pharmacometrics & Systems Pharmacology, 2022 | 8 | 2022 |
Spatiotemporal modeling of membrane receptors ÁM Halász, MMC Pryor, BS Wilson, JS Edwards Modeling Cellular Systems, 1-37, 2017 | 3 | 2017 |
Minimal physiologically-based pharmacokinetic (mPBPK) metamodeling of target engagement in skin informs anti-IL17A drug development in psoriasis VS Ayyar, JB Lee, W Wang, M Pryor, Y Zhuang, T Wilde, A Vermeulen Frontiers in Pharmacology, 1138, 2022 | 2 | 2022 |
Multiscale modeling of cancer. bioRxiv KA Norton, MMMC Pryor, AS Popel | 2 | 2015 |
2 Strategic Vision for Integrated Process Analytical Technology and Advanced Control in Biologics Manufacturing MMS Amand, PG Millili, MM McCabe, BA Ogunnaike PAT Applied in Biopharmaceutical Process Development and Manufacturing: An …, 2011 | 2 | 2011 |
Brief report: higher fentanyl exposures require higher doses of naloxone for successful reversals in a quantitative systems pharmacology model RB Moss, MMC Pryor, R Baillie, K Kudrycki, C Friedrich, M Reed, ... | 1 | 2021 |
Pan AMPK Activation Protects Tubules in Rat Ischemic Acute Kidney Injury H Frikke-Schmidt, K Albarazanji, J Qi, D Frederick, J Steffen, ... Journal of Pharmacology and Experimental Therapeutics, 2024 | | 2024 |
Differential Renal Responses to Dexamethasone in Rats and Mice Following AKI: SA-PO164 H Frikke-Schmidt, S Beck, MM Pryor, R Meng, J Strizziere, MM Rankin, ... Journal of the American Society of Nephrology 34 (11S), 769, 2023 | | 2023 |
USING MECHANISTIC QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODELS TO CONNECT BIOMARKERS TO CLINICAL DISEASE ACTIVITY SCORES-EXAMPLES IN ATOPIC DERMATITIS (AD) AND PSORIASIS (PSO). C Friedrich, R Baillie, M Weis, M Pryor, V Hurez, K Kudrycki, M Reed CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S115-S115, 2020 | | 2020 |
Quantitative Systems Pharmacology Model to Quantify Benefits of DAAO Inhibition in Schizophrenia S Iadevaia, C Friedrich, M Pryor, C Witt, L Zhang, L Xu, H Faessel, ... JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 45, S103-S104, 2018 | | 2018 |
Development of a Quantitative Systems Pharmacology (QSP) Model, the Respiratory PhysioPD (TM) Platform, to Investigate Biological Mechanisms Underlying Bronchoconstriction C Friedrich, B Weber, M Pryor, C Witt, J Borghardt, B Disse, C Dallinger, ... JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 45, S16-S17, 2018 | | 2018 |
Using Mechanistic Physiological Models to Investigate Responder/Non-Responder Attributes Retrospectively and Prospectively to De-Risk Drug Development C Friedrich, M Reed, R Baillie, K Kudrycki, M Weis, M Pryor, D Chung JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 44, S78-S78, 2017 | | 2017 |
PhysioPD™ Research Enhances Dermatology Research and Drug Development Using Mechanistic Physiological Modeling C Friedrich, K Kudrycki, M Weis, M Pryor, V Hurez, R Baillie, M Reed JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 44, S78-S79, 2017 | | 2017 |
PhysioPD TM Research Utilizes Mechanistic Physiological Models to Enhance Immunology Research and Drug Development K Kudrycki, M Weis, M Pryor, R Baillie, V Hurez, D Chung, M Reed, ... JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 44, S51-S51, 2017 | | 2017 |
717 Mechanistic physiological modeling as a tool for enhancing dermatology research C Friedrich, K Kudrycki, M Weis, M Reed, M Pryor, R Baillie Journal of Investigative Dermatology 137 (5), S123, 2017 | | 2017 |